8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934

August 20, 2003 (August 18, 2003)
Date of Report (Date of earliest event reported)

SPECTRUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-28782	93-0979187
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)
157 Technology Drive Irvine, California		92618
(Address of principal executive offices)		(Zip Code)

(949) 788-6700

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

	Item 5. Other Events
	Item 7. Exhibits
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Item 5. Other Events

     On August 18, 2003, Spectrum Pharmaceuticals, Inc. (the “Company”) and Lannett Company, Inc. announced that they have entered into an exclusive supply, marketing and distribution agreement for ciprofloxacin.

     A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

Item 7. Exhibits

Exhibits:
99.1	Press release dated August 18, 2003.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SPECTRUM PHARMACEUTICALS, INC.
Date: August 20, 2003	By:	/s/ Rajesh C. Shrotriya
	Name: Title:	Rajesh C. Shrotriya, M.D. Chairman, Chief Executive Officer and President

2

EXHIBIT INDEX

Exhibits:
99.1	Press release dated August 18, 2003.

EX-99.1 3 a92618exv99w1.htm EXHIBIT 99.1

EXHIBIT 99.1

Contacts:

John McManus
Spectrum Pharmaceuticals, Inc.
(949) 788-6700, Ext. 247

Spectrum Pharmaceuticals and Lannett Company announce exclusive supply
and distribution agreement for ciprofloxacin

     IRVINE, Calif., August 18, 2003 – Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Lannett Company, Inc. (AMEX: LCI) today announced that they have entered into an exclusive supply, marketing and distribution agreement for ciprofloxacin. Ciprofloxacin is the chemical ingredient in Cipro®, a drug marketed by Bayer Corporation. Cipro® is widely used to treat bacterial infections, and estimated annual worldwide sales exceed $1 billion.

     Lannett will receive ciprofloxacin through Spectrum’s NeoJB subsidiary, which is a joint venture between Spectrum and J.B. Chemicals & Pharmaceuticals, Ltd. (Bombay Stock Exchange: JBCPL). Upon approval of the ANDA and expiration of the patent, JBCPL will manufacture and supply ciprofloxacin for NeoJB. The Company hopes to generate revenue from the sale of ciprofloxacin in 2004.

     “We are excited about the opportunity to join with Lannett to market and distribute our first generic drug, ciprofloxacin”, stated Rajesh C. Shrotriya, Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. “Lannett has a long history in the generic industry, and has used its strengths recently to rapidly grow its sales and profits from generic drugs. We believe that Lannett’s growing base of wholesale distributors, mail order distributors, wharehousing chains and retail chains will maximize our opportunities for Ciprofloxacin sales.”

     Last year, Spectrum and JBCPL formed NeoJB LLC to enable Spectrum to benefit from JBCPL’s high quality, lower cost drug manufacturing capabilities through the sale of JBCPL’s generic drugs in the United States. JBCPL will benefit from Spectrum’s skills in managing the regulatory and marketing functions in the United States. NeoJB LLC is an 80% and 20% joint venture of Spectrum and a subsidiary of J B Chemicals & Pharmaceuticals Ltd. respectively. JBCPL is an internationally known pharmaceutical company headquartered in Mumbai, India

more...

2

     Spectrum Pharmaceuticals’ primary focus is to develop in-licensed drugs for the treatment and supportive care of cancer patients. The Company’s lead drug, satraplatin, is a phase 3 oral, anti-cancer drug being co-developed with GPC Biotech AG. Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin’s lymphoma. Eoquin™ is being studied in the treatment of superficial bladder cancer, and may have applications as a radiation sensitizer. The Company is actively working to develop, seek approval for and oversee the marketing of generic drugs in the U.S. Spectrum also has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, mild cognitive impairment and pain, which it is actively seeking to out-license or co-develop. For additional information, visit the Company’s web site at www.spectrumpharm.com.

     This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company’s reports filed with the Securities and Exchange Commission.

####

GRAPHIC 4 a92618a9261800.gif GRAPHIC begin 644 a92618a9261800.gif M1TE&.#EA6`$P`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2 M4EI:6F-C8VMK:W-SX2$A(R,C)24E)RWN?GY^\84N\A4N\A6N_O[_<84O<86O_=:>_=:A/=C>_=CA/=CC/=KC/=SC/=SE/=[E/=[G/>$ MG/>$I?>,I?>,K?>4I?>4K?>EM?>EO?>MO?>MQO>UO?>UQO>USO>] MQO>]SO?&SO?&UO?.UO?.WO?6WO?W]_]:A/]CA/]SE/][E/][G/^$G/^,I?^, MK?^4I?^4K?^WO_>Y__GY__G[__O[__O]__W]_______________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________RP`````6`$P```(_@#A"!Q(L*#!@P@3*ES(L*'# MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)4V$& M.!$:+#A@P``!`$"#"AT*M(`""@HI/&"0H*?3IU"?*EC@0,+$FQ$<+&@:M:N! M!`XL.,0`!X).!%ZC'E``06`&"%S3RIV+X`$<$`@Q3-`ZMRN"!0S:DE4X@0%/ M`P<:3(A(H<'A`PP63RR,UL`"NTT42FA0>4%;CA@<&!A`M+1IH@&L%I2`X.?I MUT0%$%!0@6$%!J,#P'X=P&Y""@M&[WX]0`+IX/RD2?0<%!# M@_7Y#>5;01C>J6,!T6:Z8P`,-"E2AB`9TN2)/L#E` MT)BF&=#0EAW>U)`"$AHT7Y@4A7B:`G#P9]$&\1&5P%A,$J6F@VR>9H":&KPZE`$##;1`J\1H-$$L%G'T(]#\2G0JJ4IH"M%%P0Z5``-H/I1!;!! ME"A1L3HD`6\$(3N4`=(FY"U[1!;< M:]Z7<%!0&UG+,@3L:P,NE(''0:D)Z&L+&(0PPIG.G&JJ"!-$`6SBA43M:X>^ MV2NHHJ[YFL,*02Q`N0=)D#%0`CA`;+H#5'2Y"P3-=4.BX M"T2!LX3#\4#Q:$M46U.7#Q?`Y_6R7?R.:.M9FKL"/0`[C=SI?MJ%)!EN&N*N M#IV\?.==/!#$2"=TN<0$6A]08D:0"5#//0XH'OTN@@&158`"$8"`!#DS`+H! M,'QP@-S8P/8UL8EM`-1I@/X&`AM2L2"*PAT!L M<7"X`'F0(P`&E$P@_ANXUK<29YH!."]5MN-=02@6&X+`ZS0P*LD#PKM#[ED,NA3WK^,I$2#<(_(I8&@$!,HVEX=)`I$D5U M<'!?I4P8$@$."#8IRXC3CO9#B0@.-6+LB.].`SSB(,\^0BQ-`!+PH6XICR%* MPC#RJA0*K8.H\<$EL-.&)$(JFQ4W)$?J59 M8-+LUS0!!@5:X:(E4`902()H0'-GA(.^1#1"BM@.CIK1B@(4D(!I5G.:UJ2F M`G*TF]&QSC1KRT@$3(\>4DK3P*\AI7N?02BP MT``5`*KL)$KT.'*!JU4O(1%`"RB%!$H#K)6M]\(VO?.=+W_K:][[XS:]^]\O?_M(W M4Q0(<,@"7+(+E->_&<$9#@/[X6(&IJ9(\2I)-Y$S M'!9<$`",535(`?3RX(P[",CV(&T@`Q&^8`1:DR$A90#"%GZPZRX,&2%X`$+GA(BNLXYKOHSB>#@JRI!_(`V0QJFR>24P)Z.(`:M24Z/)EFB0J` M`*,L``%DJX\&B+>6/%80<5L3P%_P/8`P:6#?:]G)NC0(COL$@"'QJ:D5'T@#`J#R M!2B`Y0X10ZV-`(9:'V$,;S#(&'A-]2SP^M<$80,/%<)`2C.#\R%,75!2E]`/"X0`!@'9#."P"`4Y`!E@73@6W`2$" M@%=N'4`"(]`!5]`0)U-A3H(B2I4A)E0`V9(9"',32D$:`Z$["Q0=2@(`)@0` M2F1;R44>K<(KB01I)P('M5$;7`4`5C%%!D$GK0=2Y7)RR=-,NI(S'"@U`+!. M0YAA8Z8F-(80.Z>%/Z`% M/Z`&!3%L/4`%.:!^YT<%0%`009!VRQ8%R_9^!C$#U;9_<%=M,E`0/-!M)X`" M`8@"*8`"!<$&@9>`_G\W`H1H,NVV$"]&(1(C`:)E(PA@X<44X$)F7B8$3 M`*MA@D)7(RI"<\N!B3D%!R!U`$2BBCW1%AU7$+I3>]6S,]&S)0L1`42B(KB1 MB1"2)!2`&V[5;PZP/#J7B4R83'``A;,'30\A!M;WC&%0!-P:^`' M!.#W`V60=5U'!6"W`U>0`^/8`P9!`W)H=N]G=D10$/@7=],V;=16$#0`B'@W MB(*(=SY`$$K`@"00`N7V`2/`@"?@$&-69L7(1@/`'[I76T3X@0+`6R*8-P!P M2J#8!!74:0*!`:^G3+AG$&T&@P'@)GCA*!=0`9EB@P61(;*X@YE8(4Q^902?H4T$]`R$$!()"20#9LC,&4"XR0GLDA'J(^9&-8WAK M$@`PLG.KI!OU`2&2073S$BK&0@$2=!#*QX0JAC'&`@$;-Q#K0H("40$0X%EC M,&O7=WU/^05;2!!GL(V[Q@7?!P1_.1!7H`-6_H!^:(@%P]8%U0@'8%`#,3_,&1`H`8"#")C?@ZG71ZCVE\KVDL2R**/)$`I'&;&%@FHB4` M2O4Z!6`C/D$`E81P&H46JLB:`X%P)8IGT$)OGFDC!^"9UG%Z9?*@)=J(D"D0 M4J.AHY$U[G.#,\IS_6,U8Z4^&HJC1&A8:QD&4,ETR_D%USD00?"%5+=K7V`0 M1O"5YA>6/;"5!%%VZ,AL99<#!H$%U?8$\HA_86`0+5"?`WB/>U@0,L"7B3B0 M8]D02:@N"*$_2-$6_A]B%1\R0IEAE`B!)S>1,@W2>@(QDWUR$(M!J`&%$Z/:3'8A&`215]!$:E73F&7QJE1!%^`?;46 M!DIP$$RP!5@9AKP&!`9H$%LPCN)(CCD0!``=01A`_@'`VX* M`SQP$%]`G]TV@"S`?@6A`N?F`2(PD".0;C!VKA=1`0:0E"?Q!F6@=$TG!DR0 M$&@P!-09?EV*$&T0!#S0=3G0`VIY$&.0`\MZGCP`K5EG!6\W;3*`EP=!!#!P MGRHP`][:=C'@=^5F`G2'KAQ+$7_*$FJ`!L'*$&5@90VQ!$*6=$>`L,@6,00! MJQ#7^`,.X0,Z(+,=>[,XF[,ZN[,\V[,^^[-`&[1".[1$6[1&>[1(F[1*6[0! $`0``.S\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----

EX-99.1

Exhibit 99.1